Reunion Neuroscience has filed a lawsuit Monday against Mindset Pharma Inc. in the United States District Court for the District of New Jersey, alleging that Mindset knowingly copied Reunion’s RE104 compound and misleadingly presented that exact composition to the Patent Office as Mindset’s invention while applying for U.S. Patent No. 11,591,353. Reunion thus seeks to add the original and sole inventor of Reunion’s RE104 – Dr. Nathan Bryson, Reunion’s Chief Scientific Officer – as an inventor of the ‘353 Patent. Reunion additionally asserts claims for, among others, co-ownership of the ‘353 Patent, inequitable conduct in the prosecution of the ‘353 Patent, and breach of contract.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on REUN:
- Reunion Neuroscience Files Lawsuit Against Mindset Pharma
- Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference
- Reunion Neuroscience reports Q3 EPS (C$1.07) vs. (C$0.51) last year
- Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results
- Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET
